Skye Bioscience, Inc. (SKYE)

Market Cap	81.91M
Revenue (ttm)	n/a
Net Income (ttm)	-21.24M
Shares Out	30.34M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	431,481
Open	2.850
Previous Close	2.860
Day's Range	2.663 - 3.090
52-Week Range	2.250 - 19.410
Beta	1.77
Analysts	Buy
Price Target	18.67 (+591.48%)
Earnings Date	Feb 9, 2025

About SKYE

Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: SKYE
• Website: https://skyebioscience.com

Analyst Forecast

According to 6 analysts, the average rating for SKYE stock is "Buy." The 12-month stock price forecast is $18.67, which is an increase of 591.48% from the latest price.

Price Target

$18.67

(591.48% upside)

Analyst Consensus: Buy